急性心肌梗死合并心源性休克诊治进展

李云曌; 吴辉; 刘滴

doi:10.13201/j.issn.1001-1439.2020.08.003

急性心肌梗死合并心源性休克诊治进展

- 三峡大学心血管病研究所宜昌市中心人民医院心内科(湖北宜昌, 443003)
基金项目:
国家自然科学基金青年项目(No:81600234)

详细信息

通讯作者: 吴辉,E-mail:cardiology_wh@126.com

中图分类号: R541.6

收稿日期: 2019-12-31

修回日期: 2020-05-21

Progress in diagnosis and treatment of acute myocardial infarction with cardiogenic shock

- Institute of Cardiovascular Diseases, China Three Gorges University & Department of Cardiology, Yichang Central People's Hospital, Yichang, Hubei, 443003, China

More Information

Corresponding author: WU Hui, E-mail: cardiology_wh@126.com

Received Date: 31 December 2019

Revised Date: 21 May 2020

摘要

摘要: 心源性休克(CS)是急性心肌梗死(AMI)最严重的并发症之一,也是导致患者死亡最常见的原因。血管活性药物、机械循环支持、早期血运重建等措施广泛应用于AMI合并CS的急诊救治,但AMI合并CS的病死率仍居高不下。本文主要探讨近年来AMI合并CS的临床诊治进展。
- 急性心肌梗死 /
- 心源性休克 /
- 经皮冠状动脉介入治疗 /
- 机械循环支持
Abstract: Cardiogenic shock(CS) is one of the most serious complications of acute myocardial infarction(AMI) and the most common cause of death.In the emergency treatment of AMI combined with CS,the application of vascular drugs,support for mechanical circulation,and early revascularization are widely used,but the mortality rate of AMI combined with CS is still high.This article mainly discusses the latest progress of clinical diagnosis and treatment of AMI combined with CS.
- acute myocardial infarction /
- cardiogenic shock /
- percutaneous coronary intervention /
- mechanical cycle support

HTML全文

参考文献(27)

[1]	Backhaus T,Fach A,Schmucker J,et al.Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-Segment elevation myocardial infarction:results from the Bremen STEMI Registry[J].Clin Res Cardiol,2018,107(5):371-379.
[2]	Thiele H,Akin I,Sandri M,et al.PCI strategies in patients with acute myocardial infarction and cardiogenic shock[J].N Engl J Med,2017,377(25):2419-2432.
[3]	Baran DA,Grines C,Bailey S,et al.SCAI clinical expert consensus statement on the classification of car Diogenic shock:This document was endorsed by the American College of Cardiology (ACC),the American Heart Association (AHA),the Society of Critical Care Medicine (SCCM),and the Society of Thoracic Surgeons (STS) in April 2019[J].Catheter Cardiovasc Interv,2019,94(1):29-37.
[4]	Pöss J,Köster J,Fuernau G,et al.Risk stratification for patients in cardiogenic shock after acute myocardial infarction[J].J Am Coll Card,2017,69(15):1913-1920.
[5]	Reignier J,Boisrame-Helms J,Brisard L,et al.Enteral versus parenteral early nutrition in ventilated adults with shock:a randomised,controlled,multicentre,open-label,parallel-group study (NUTRIREA-2)[J].Lancet,2018,391(10116):133-143.
[6]	Thiele H,Zeymer U,Neumann FJ,et al.Intraaortic balloon support for myocardial infarction with cardiogenic shock[J].N Engl J Med,2012,367(14):1287-1296.
[7]	Fuernau G,Beck J,Desch S,et al.Mild hypothermia in cardiogenic shock complicating myocardial infarction:the randomized SHOCK-COOL trial[J].Circulation,2019,139(4):448-457.
[8]	De Backer D,Biston P,Devriendt J,et al.Comparison of dopamine and norepinephrine in the treatment of shock[J].N Engl J Med,2010,362(9):779-789.
[9]	Levy B,Clere-Jehl R,Legras A,et al.Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction[J].J Am Coll Card,2018,72(2):173-182.
[10]	Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2016,37(27):2129-2200.
[11]	Fuhrmann JT,Schmeisser A,Schulze MR,et al.Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction[J].Crit Care Med,2008,36(8):2257-2266.
[12]	Cholley B,Caruba T,Grosjean S,et al.Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass:the licorn randomized clinical trial[J].JAMA,2017,318(6):548-556.
[13]	Hochman JS,Sleeper LA,Webb JG,et al.Early revascularization in acute myocardial infarction complicated by cardiogenic shock.SHOCK Investigators.Should we emergently revascularize occluded coronaries for cardiogenic shock[J].N Engl J Med,1999,341(9):625-634.
[14]	Hochman JS,Sleeper LA,Webb JG,et al.Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction[J].JAMA,2006,295(21):2511-2515.
[15]	Jeger RV,Radovanovic D,Hunziker PR,et al.Ten-year trends in the incidence and treatment of cardiogenic shock[J].Ann Intern Med,2008,149(9):618-626.
[16]	Neumann FJ,Sousa Uva M,Ahlsson A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization[J].Eur Heart J,2019,40(2):87-165.
[17]	Kochar A,Al-Khalidi HR,Hansen SM,et al.Delays in primary percutaneous coronary intervention in ST-Segment elevation myocardial infarction patients presenting with cardiogenic shock[J].JACC Cardiovasc Interv,2018,11(18):1824-1833.
[18]	Lemor A,Basir MB,Patel K,et al.Multi-versus culprit-vessel percutaneous coronary intervention in cardiogenic shock[J].JACC Cardiovasc Interv,2020,13(10):1179-1181.
[19]	Thiele H,Akin I,Sandri M,et al.One-year outcomes after PCI strategies in cardiogenic shock[J].N Engl J Med,2018,379(18):1699-1710.
[20]	Smilowitz NR,Alviar CL,Katz SD,et al.Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock[J].Am Heart J,2020,S0002-8703(20)30080-6.
[21]	Thiele H,Zeymer U,Thelemann N,et al.Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction:long-term 6-year outcome of the randomized IABP SHOCK Ⅱ trial[J].Circulation,2018.doi:10.1161/CIRCULATIONAHA.118.038201.
[22]	Ibanez B,James S,Agewall S,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-Segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-Segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart J,2018,39(2):119-177.
[23]	Ouweneel DM,Eriksen E,Sjauw KD,et al.Impella CP versus intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock.The IMPRESS in Severe Shock trial[J].J Am Coll Card,2017,69(3):278-287.
[24]	Thiele H,Jobs A,Ouweneel DM,et al.Percutaneous short-term active mechanical support devices in cardiogenic shock:a systematic review and collaborative meta-analysis of randomized trials[J].Eur Heart J,2017,38(47):3523-3531.
[25]	Schrage B,Ibrahim K,Loehn T,et al.Impella support for acute myocardial infarction complicated by cardiogenic shock:a matched-pair IABP-SHOCK Ⅱ trial 30-day mortality analysis[J].Circulation,2019,139(10):1249-1258.
[26]	Ouweneel DM,Schotborgh JV,Limpens J,et al.Extracorporeal life support during cardiac arrest and cardiogenic shock:a systematic review and meta-analysis[J].Intensive Care Med,2016,42(12):1922-1934.
[27]	Becher PM,Schrage B,Sinning CR,et al.Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support[J].Circulation,2018,138(20):2298-2300.